Cynata Therapeutics Limited
Cynata Therapeutics Limited, together with its subsidiaries, engages in the development and commercialization of proprietary induced pluripotent stem cell and mesenchymal stem cell technology under the Cymerus brand for human therapeutic use in Australia. The company's lead therapeutic product candidate is CYP-001, which has completed Phase 2 clinical trial for the treatment of graft versus host … Read more
Cynata Therapeutics Limited (CYYNF) - Total Liabilities
Latest total liabilities as of June 2025: $1.22 Million USD
Based on the latest financial reports, Cynata Therapeutics Limited (CYYNF) has total liabilities worth $1.22 Million USD as of June 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Cynata Therapeutics Limited - Total Liabilities Trend (2007–2025)
This chart illustrates how Cynata Therapeutics Limited's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Cynata Therapeutics Limited Competitors by Total Liabilities
The table below lists competitors of Cynata Therapeutics Limited ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
NHOA S.A
PINK:ENGPF
|
USA | $233.15 Million |
|
Globon Co. Ltd
KQ:019660
|
Korea | ₩5.35 Billion |
|
Crown Crafts Inc
NASDAQ:CRWS
|
USA | $39.11 Million |
|
Echomarketing Co.Ltd
KQ:230360
|
Korea | ₩150.39 Billion |
|
Redefine Properties Ltd
JSE:RDF
|
South Africa | ZAC49.65 Billion |
|
Infrea AB
ST:INFREA
|
Sweden | Skr593.90 Million |
Liability Composition Analysis (2007–2025)
This chart breaks down Cynata Therapeutics Limited's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 4.40 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.20 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.17 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Cynata Therapeutics Limited's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Cynata Therapeutics Limited (2007–2025)
The table below shows the annual total liabilities of Cynata Therapeutics Limited from 2007 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-06-30 | $1.22 Million | +3.85% |
| 2024-06-30 | $1.17 Million | -48.19% |
| 2023-06-30 | $2.26 Million | -12.66% |
| 2022-06-30 | $2.59 Million | +61.57% |
| 2021-06-30 | $1.60 Million | +132.23% |
| 2020-06-30 | $689.74K | -46.04% |
| 2019-06-30 | $1.28 Million | +71.32% |
| 2018-06-30 | $746.15K | +91.52% |
| 2017-06-30 | $389.60K | -12.92% |
| 2016-06-30 | $447.38K | +19.18% |
| 2015-06-30 | $375.39K | +426.53% |
| 2014-06-30 | $71.30K | -52.37% |
| 2013-06-30 | $149.70K | -8.21% |
| 2012-06-30 | $163.09K | -33.68% |
| 2011-06-30 | $245.93K | -22.37% |
| 2010-06-30 | $316.81K | -30.87% |
| 2009-06-30 | $458.26K | +292.08% |
| 2008-06-30 | $116.88K | -20.58% |
| 2007-06-30 | $147.16K | -- |